Summary
For Year 2026-27, Concord Biotech reports the following shareholding: Total Promoters at 44.08%, Mutual Fund at 4.3%, Insurance at 3.89%, Foreign Institutional Investors at 7.79%, Domestic Institutional Investors at 1.04%, and Retail at 38.9%. This breakdown provides a quick snapshot of ownership distribution for Concord Biotech in 2026-27.
Concord Biotech FAQs
As of 04-2026, the promoter shareholding in Concord Biotech stands at 44.08% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Concord Biotech is 7.79% and 1.04% respectively.
The retail shareholding of the Concord Biotech is 38.9%.
Changes in shareholding patterns of Concord Biotech can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Concord Biotech are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
